We commit to making these branded therapeutic treatments accessible and

We commit to making these branded therapeutic

This preview shows page 75 - 77 out of 98 pages.

We   commit   to   making   these   branded   therapeutic   treatments   accessible   and affordable to patients  while also ensuring that we can continue to meet our ‘invest and innovate’ obligations outlined in Principle 1. Providing our treatments to patients is not a straightforward exercise.   We have to go through many decision makers and intermediaries to make sure that our products are available to the patients who need them.   That means government payers, regulators, private insurers, and PBMs to name a few.    We commit to working with decision makers and intermediaries to make our products accessible to all people who need them.   This often includes giving discounts and paying rebates.   The current pricing environment is highly competitive with large payers making decisions that may limit patient access to our medicines in favor of a competitor based on the latter’s willingness to pay more rebates.  In order to ensure that patients and physicians have access to a full array of medical options, we believe that these intermediaries should have open access to formularies whenever possible.  We employ green processes, materials, practices, equipment and technologies where possible to enhance conservation and reduce waste. We seek to utilize environmentally responsible building practices and materials in the construction and renovation of our global   facilities.   And   we   encourage   partnerships   with   suppliers   who   share   our commitment   to   environmental   responsibility.Together,   we   are   working   to   ensure   a cleaner, greener Allergan. 42 42 75
Image of page 75
4. R ECKITT B ENCKISER G ROUP PLC (C ONSUMER S TAPLES ): We are committed to appropriately educating physicians about our medicines so that they can be used in the right patients for the right conditions.   This is an ongoing effort and one that we take pride in doing well because outcomes matter to everyone; patients and their advocates, physicians, payers and policy makers.  I will talk more about our education principle in a subsequent blog.  There is no joy on my part when a company finds itself in the public spotlight – the target of societal ire.  I take comfort in reading about new treatments that improve and save lives.  The public’s expectation is that we exist to heal and cure.  It’s an expectation that mirrors our own. Our biopharma industry is vital and has made profound contributions that have increased life expectancy and dramatically improved health during the last generation.  For me, it is a special privilege to work in this industry at this time of bubbling science and exciting innovation.   For our industry to remain a vibrant and important part of the healthcare
Image of page 76
Image of page 77

You've reached the end of your free preview.

Want to read all 98 pages?

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes